| Lower risk of heart failure and death in patients initiated on sodium-glucose cotransporter-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL study (comparative … M Kosiborod, MA Cavender, AZ Fu, JP Wilding, K Khunti, RW Holl, ... Circulation 136 (3), 249-259, 2017 | 729 | 2017 |
| Cardiovascular events associated with SGLT-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL 2 study M Kosiborod, CSP Lam, S Kohsaka, DJ Kim, A Karasik, J Shaw, N Tangri, ... Journal of the American College of Cardiology 71 (23), 2628-2639, 2018 | 467 | 2018 |
| Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs … KI Birkeland, ME Jørgensen, B Carstensen, F Persson, HL Gulseth, ... The lancet Diabetes & endocrinology 5 (9), 709-717, 2017 | 377 | 2017 |
| Dapagliflozin is associated with lower risk of cardiovascular events and all‐cause mortality in people with type 2 diabetes (CVD‐REAL Nordic) when compared with dipeptidyl … F Persson, T Nyström, ME Jørgensen, B Carstensen, HL Gulseth, ... Diabetes, Obesity and Metabolism 20 (2), 344-351, 2018 | 216 | 2018 |
| Upper normal blood pressures predict incident atrial fibrillation in healthy middle-aged men: a 35-year follow-up study I Grundvold, PT Skretteberg, K Liestøl, G Erikssen, SE Kjeldsen, ... Hypertension 59 (2), 198-204, 2012 | 209 | 2012 |
| Effects of interactive patient smartphone support app on drug adherence and lifestyle changes in myocardial infarction patients: A randomized study N Johnston, J Bodegard, S Jerström, J Åkesson, H Brorsson, J Alfredsson, ... American heart journal 178, 85-94, 2016 | 186 | 2016 |
| CVD-REAL Investigators and Study Group. Lower risk of heart failure and death in patients initiated on sodium-glucose cotransporter-2 inhibitors versus other glucose-lowering … M Kosiborod, MA Cavender, AZ Fu, JP Wilding, K Khunti, RW Holl, ... Circulation 136 (3), 249-59, 2017 | 184 | 2017 |
| Heart failure and chronic kidney disease manifestation and mortality risk associations in type 2 diabetes: a large multinational cohort study KI Birkeland, J Bodegard, JW Eriksson, A Norhammar, H Haller, ... Diabetes, obesity and metabolism 22 (9), 1607-1618, 2020 | 163 | 2020 |
| Incidence, prevalence and mortality of type 2 diabetes requiring glucose-lowering treatment, and associated risks of cardiovascular complications: a nationwide study in Sweden … A Norhammar, J Bodegård, T Nyström, M Thuresson, JW Eriksson, ... Diabetologia 59, 1692-1701, 2016 | 139 | 2016 |
| Prevalence, outcomes, and cost of chronic kidney disease in a contemporary population of 2· 4 million patients from 11 countries: The CaReMe CKD study J Sundström, J Bodegard, A Bollmann, MG Vervloet, PB Mark, A Karasik, ... The Lancet Regional Health–Europe 20, 2022 | 136 | 2022 |
| Sulphonylurea compared to DPP-4 inhibitors in combination with metformin carries increased risk of severe hypoglycemia, cardiovascular events, and all-cause mortality JW Eriksson, J Bodegard, D Nathanson, M Thuresson, T Nyström, ... Diabetes research and clinical practice 117, 39-47, 2016 | 130 | 2016 |
| Lower risk of heart failure and death in patients initiated on SGLT-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL study. M Kosiborod, MA Cavender, AZ Fu, JP Wilding, K Khunti, RW Holl, ... Circulation 136 (3), 249-259, 2017 | 121 | 2017 |
| SGLT-2 inhibitors and cardiovascular risk: an analysis of CVD-REAL MA Cavender, A Norhammar, KI Birkeland, ME Jørgensen, JP Wilding, ... Journal of the American College of Cardiology 71 (22), 2497-2506, 2018 | 116 | 2018 |
| Exercise testing of healthy men in a new perspective: from diagnosis to prognosis G Erikssen, J Bodegard, JV Bjørnholt, K Liestøl, DS Thelle, J Erikssen European heart journal 25 (11), 978-986, 2004 | 103 | 2004 |
| Heart failure drug titration, discontinuation, mortality and heart failure hospitalization risk: a multinational observational study (US, UK and Sweden) G Savarese, J Bodegard, A Norhammar, P Sartipy, M Thuresson, ... European journal of heart failure 23 (9), 1499-1511, 2021 | 101 | 2021 |
| Population study of disease burden, management, and treatment of bipolar disorder in S weden: a retrospective observational registry study A Carlborg, L Ferntoft, M Thuresson, J Bodegard Bipolar Disorders 17 (1), 76-85, 2015 | 97 | 2015 |
| Novel oral glucose‐lowering drugs are associated with lower risk of all‐cause mortality, cardiovascular events and severe hypoglycaemia compared with insulin in patients with … T Nyström, J Bodegard, D Nathanson, M Thuresson, A Norhammar, ... Diabetes, Obesity and Metabolism 19 (6), 831-841, 2017 | 94 | 2017 |
| Effects of losartan vs candesartan in reducing cardiovascular events in the primary treatment of hypertension SE Kjeldsen, J Stålhammar, P Hasvold, J Bodegard, U Olsson, D Russell Journal of human hypertension 24 (4), 263-273, 2010 | 90 | 2010 |
| How representative of a general type 2 diabetes population are patients included in cardiovascular outcome trials with SGLT2 inhibitors? A large European observational study KI Birkeland, J Bodegard, A Norhammar, JG Kuiper, E Georgiado, ... Diabetes, Obesity and Metabolism 21 (4), 968-974, 2019 | 81 | 2019 |
| Heart failure drug treatment—inertia, titration, and discontinuation: a multinational observational study (EVOLUTION HF) G Savarese, T Kishi, O Vardeny, S Adamsson Eryd, J Bodegård, LH Lund, ... Heart Failure 11 (1), 1-14, 2023 | 80 | 2023 |
Marcus ThuressonStatisticon ABBestätigte E-Mail-Adresse bei statisticon.se
